Literature DB >> 22229059

The Use of Principal Component Analysis in MALDI-TOF MS: a Powerful Tool for Establishing a Mini-optimized Proteomic Profile.

Changli Shao1, Yaping Tian, Zhennan Dong, Jing Gao, Yanhong Gao, Xingwang Jia, Guanghong Guo, Xinyu Wen, Chaoguang Jiang, Xueji Zhang.   

Abstract

BACKGROUND: Recently, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) technology has been applied to the exploration of biomarkers for early cancer diagnosis, but more effort is required to identify a single sensitive and specific biomarker. For early diagnosis, a proteomic profile is the gold standard, but inconvenient for clinical use since the profile peaks are quantitative. It would therefore be helpful to find a minimized profile, comprising fewer peaks than the original using an existing algorithm and compare it with other traditional statistical methods.
METHODS: In the present study, principal component analysis (PCA) in the ClinProt-Tools of MALDI-TOF MS was used to establish a mini-optimized proteomic profile from gastric cancer patients and healthy controls, and the result was compared with t-test and Flexanalysis software.
RESULTS: Eight peaks were selected as the mini-optimized proteomic profile to help differentiate between gastric cancer patients and healthy controls. The peaks at m/z 4212 were regarded as the most important peak by the PCA algorithm. The peaks at m/z 1866 and 2863 were identified as deriving from complement component C3 and apolipoprotein A1, respectively.
CONCLUSIONS: PCA enabled us to identify a mini-optimized profile consisting of significantly differentiating peaks and offered the clue for further research.

Entities:  

Year:  2012        PMID: 22229059      PMCID: PMC3251008          DOI: 10.5099/aj120100085

Source DB:  PubMed          Journal:  Am J Biomed Sci        ISSN: 1937-9080


  31 in total

Review 1.  Place of pattern in proteomic biomarker discovery.

Authors:  Michael A Gillette; D R Mani; Steven A Carr
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

Review 2.  Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool?

Authors:  Anne K Callesen; Jonna S Madsen; Werner Vach; Torben A Kruse; Ole Mogensen; Ole N Jensen
Journal:  Proteomics       Date:  2009-03       Impact factor: 3.984

3.  Construction of a multiple myeloma diagnostic model by magnetic bead-based MALDI-TOF mass spectrometry of serum and pattern recognition software.

Authors:  Qing-Tao Wang; Yong-Zhe Li; Yu-Fang Liang; Chao-Jun Hu; Yu-Hua Zhai; Guan-Fei Zhao; Jian Zhang; Ning Li; An-Ping Ni; Wen-Ming Chen; Yang Xu
Journal:  Anat Rec (Hoboken)       Date:  2009-04       Impact factor: 2.064

4.  Standardized peptidome profiling of human cerebrospinal fluid by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Mathias Bruegel; Mathis Planert; Sven Baumann; Almut Focke; Florian Then Bergh; Alexander Leichtle; Uta Ceglarek; Joachim Thiery; Georg Martin Fiedler
Journal:  J Proteomics       Date:  2008-12-07       Impact factor: 4.044

Review 5.  Mass spectrometry-based clinical proteomics profiling: current status and future directions.

Authors:  Peter Findeisen; Michael Neumaier
Journal:  Expert Rev Proteomics       Date:  2009-10       Impact factor: 3.940

6.  Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer.

Authors:  Monika Pietrowska; Lukasz Marczak; Joanna Polanska; Katarzyna Behrendt; Elzbieta Nowicka; Anna Walaszczyk; Aleksandra Chmura; Regina Deja; Maciej Stobiecki; Andrzej Polanski; Rafal Tarnawski; Piotr Widlak
Journal:  J Transl Med       Date:  2009-07-13       Impact factor: 5.531

7.  Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry.

Authors:  Josep Villanueva; Arpi Nazarian; Kevin Lawlor; Paul Tempst
Journal:  Nat Protoc       Date:  2009-07-23       Impact factor: 13.491

8.  Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.

Authors:  John F Timms; Rainer Cramer; Stephane Camuzeaux; Ali Tiss; Celia Smith; Brian Burford; Ilia Nouretdinov; Dmitry Devetyarov; Aleksandra Gentry-Maharaj; Jeremy Ford; Zhiyuan Luo; Alex Gammerman; Usha Menon; Ian Jacobs
Journal:  Clin Chem       Date:  2010-01-21       Impact factor: 8.327

9.  Optimal preparation methods for automated matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling of low molecular weight proteins and peptides.

Authors:  Megan A S Penno; Matthias Ernst; Peter Hoffmann
Journal:  Rapid Commun Mass Spectrom       Date:  2009-09       Impact factor: 2.419

10.  Acid hydrolysis followed by matrix-assisted laser desorption/ionization mass spectrometry for the rapid diagnosis of serum protein biomarkers in patients with major depression.

Authors:  Li-Hua Lo; Tiao-Lai Huang; Jentaie Shiea
Journal:  Rapid Commun Mass Spectrom       Date:  2009-03       Impact factor: 2.419

View more
  13 in total

1.  Novel Method for Reliable Identification of Siccibacter and Franconibacter Strains: from "Pseudo-Cronobacter" to New Enterobacteriaceae Genera.

Authors:  Barbora Svobodová; Jiří Vlach; Petra Junková; Ludmila Karamonová; Martina Blažková; Ladislav Fukal
Journal:  Appl Environ Microbiol       Date:  2017-06-16       Impact factor: 4.792

2.  A comparative study of hollow copper sulfide nanoparticles and hollow gold nanospheres on degradability and toxicity.

Authors:  Liangran Guo; Irene Panderi; Daisy D Yan; Kevin Szulak; Yajuan Li; Yi-Tzai Chen; Hang Ma; Daniel B Niesen; Navindra Seeram; Aftab Ahmed; Bingfang Yan; Dionysios Pantazatos; Wei Lu
Journal:  ACS Nano       Date:  2013-10-01       Impact factor: 15.881

3.  S100A4 exerts robust mucosal adjuvant activity for co-administered antigens in mice.

Authors:  Arka Sen Chaudhuri; Yu-Wen Yeh; Olifan Zewdie; Nga Shan Li; Jia-Bin Sun; Tao Jin; Bin Wei; Jan Holmgren; Zou Xiang
Journal:  Mucosal Immunol       Date:  2022-06-21       Impact factor: 8.701

4.  Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.

Authors:  Ming Tong; Raiane Leão; Gina V Vimbela; Emine B Yalcin; Jared Kay; Alexander Krotow; Suzanne M de la Monte
Journal:  Mol Cell Neurosci       Date:  2017-04-21       Impact factor: 4.314

5.  Alteration of actin dependent signaling pathways associated with membrane microdomains in hyperlipidemia.

Authors:  Viorel-Iulian Suica; Elena Uyy; Raluca Maria Boteanu; Luminita Ivan; Felicia Antohe
Journal:  Proteome Sci       Date:  2015-12-01       Impact factor: 2.480

6.  Easy identification of leishmania species by mass spectrometry.

Authors:  Oussama Mouri; Gloriat Morizot; Gert Van der Auwera; Christophe Ravel; Marie Passet; Nathalie Chartrel; Isabelle Joly; Marc Thellier; Stéphane Jauréguiberry; Eric Caumes; Dominique Mazier; Carine Marinach-Patrice; Pierre Buffet
Journal:  PLoS Negl Trop Dis       Date:  2014-06-05

7.  Imaging and mapping of mouse bone using MALDI-imaging mass spectrometry.

Authors:  Yoko Fujino; Tomoko Minamizaki; Hirotaka Yoshioka; Mitsugi Okada; Yuji Yoshiko
Journal:  Bone Rep       Date:  2016-09-29

8.  Elucidating the Ramularia eucalypti species complex.

Authors:  S I R Videira; J Z Groenewald; A Kolecka; L van Haren; T Boekhout; P W Crous
Journal:  Persoonia       Date:  2014-11-20       Impact factor: 11.051

9.  Profiling and Identification of Novel Immunogenic Proteins of Staphylococcus hyicus ZC-4 by Immunoproteomic Assay.

Authors:  Lei Wang; Zhi-Wei Wu; Yan Li; Jian-Guo Dong; Le-Yi Zhang; Peng-Shuai Liang; Yan-Ling Liu; Ya-Hua Zhao; Chang-Xu Song
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

10.  Proteomic analysis of canine oral tumor tissues using MALDI-TOF mass spectrometry and in-gel digestion coupled with mass spectrometry (GeLC MS/MS) approaches.

Authors:  Sirinun Pisamai; Sittiruk Roytrakul; Narumon Phaonakrop; Janthima Jaresitthikunchai; Gunnaporn Suriyaphol
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.